Canine Cognitive Dysfunction Syndrome (CCD) is a progressive neurodegenerative condition affecting aging dogs, often compared to Alzheimer’s disease in humans. Benzal and Rodríguez (2016) reviewed advances in understanding its pathophysiology, diagnosis, and treatment, emphasizing the importance of early recognition.
CCD is underdiagnosed: while it affects at least 14% of senior dogs, fewer than 2% receive a clinical diagnosis. Symptoms, often misattributed to normal aging, are summarized by the acronym DISHA: Disorientation, altered Interactions, Sleep-wake cycle changes, House-soiling, and Activity level shifts. These behavioral changes may appear as early as seven years of age but typically worsen in later life.
Neuropathological findings in CCD include amyloid-β deposits, brain atrophy, and neuronal loss, paralleling Alzheimer’s pathology. However, there are no definitive diagnostic tests or biomarkers, making diagnosis reliant on exclusion of other causes of behavioral change. Veterinarians must carefully assess owner-reported histories to identify subtle signs.
Although CCD cannot be cured, management strategies can slow progression and improve quality of life. These include drug therapies to enhance cognition and reduce anxiety, antioxidant-rich diets and nutraceutical supplements to support neural health, and environmental enrichment to maintain mental stimulation. The review emphasizes the value of a multimodal approach tailored to individual dogs.
The authors argue that raising awareness among owners and veterinarians is essential for earlier intervention, better management, and improved welfare for aging dogs facing cognitive decline.
Source: Benzal, A. S., & Rodríguez, A. G. (2016). Recent developments in Canine Cognitive Dysfunction Syndrome. Pages 47–59.
